There has been much emphasis on the Todos Tollovir Phase 2 Clinical Trial and anticipation that the results may be positive. If that turns out to be the case then it will be a game changer for the company. What we do know now is that the Tollovid products already on the market have demonstrated that they help strengthen ones immune system. With the discovery of Omicron and other variants, people may start to realize that an investment in improving their immunity is money well spent. Todos seems to be ideally poised to assist in that effort.
Market Data 
Markets 
AI
